SA, Ana; FREITAS, Sara; ALVES, Glória    COTTER, Jorge. The Impact of Biological Drugs in Patients with Rheumatoid Arthritis. []. , 25, 3, pp.201-207. ISSN 0872-671X.  https://doi.org/10.24950/rspmi/original/355/3/2018.

Introduction: Rheumatoid arthritis (RA) is a disabling autoimmune disease. Biological agents have dramatically altered the natural course of the disease. This study evaluated the impact of these drugs on patients’ lives and analyzed the factors responsible for a better response to treatment. Material and Methods:Retrospective study of 80 patients diagnosed with RA and treated with biological drugs between January 2004 and April 2015 in Hospital Senhora de Oliveira, Guimarães (Portugal). Patients were retrospectively evaluated before and 6 months after biological treatment. Results: A total of 80 patients with RA were analyzed, 62 women (77.5%) and 18 men (22.5%), with a mean age of 45.5 (± 13.0) years. About 67.1% of the patients were positive for rheumatoid factor and 55.4% were positive for anti-citrulline antibodies. There was an association between the positivity of these antibodies and RA diagnosis (p = 0.001). Etanercept was the biological drug used in most patients (75.9%). Fifteen (18.8%) patients discontinued the biological drug and 19 (24.1%) switched to another. In 6 months of biological treatment, patients had a significant reduction in erythrocyte sedimentation rate, in C-reactive protein levels and in Disease Activity Score (DAS28), which decreased from 4.91 ± 1.31 to 2.53 ± 1.10 (p = 0.001). Discussion: The results confirm the many benefits of biological drugs in patients with RA. Conclusion:Biological drugs significantly reduce the level of disease activity, inflammatory parameters and symptoms of patients with RA

: Antirheumatic Agents/therapeutic use; Arthritis, Rheumatoid/drug therapy; Biological Products/therapeutic use; Etanercept; Receptors, Tumor Necrosis Factor.

        · |     · |     · ( pdf )